A MOU signed between PharMed Business Group and Access Pharma Group in Montreal on March 8, 2016 to promote the 2016 CRO Outsourcing Forum

PharMed 400x200

10 Mar A MOU signed between PharMed Business Group and Access Pharma Group in Montreal on March 8, 2016 to promote the 2016 CRO Outsourcing Forum

.

.

.

PharMed 400x200  A MOU signed between PharMed Business Group and Access Pharma Group in Montreal on March 8, 2016 to promote the 2016 CRO Outsourcing Forum PharMed

 Press release   APG-300x100  A MOU signed between PharMed Business Group and Access Pharma Group in Montreal on March 8, 2016 to promote the 2016 CRO Outsourcing Forum APG

.

.

 

 

A Memorandum of understanding (MOU) was signed on March 8 between Access Pharma Group and PharMed Business Group, the Health Industries Manufacturing and R&D Outsourcing Network of Canada. The two parties agreed to develop a cooperation in view to mutually promote and expand their respective activities in order to reach a larger audience and increase the generated profits.

The parties recognize the importance to join their efforts and complementary competences in order to increase the scope of their services and accelerate the growth of their respective activities in order to develop new business opportunities with the combined force of their teams.

The main objective is to popularize the PharMed forum as a meeting point for CROs, drug and diagnostics manufacturers, biotech companies, generics and specialty products manufactures, device companies, contractual R&D centers, clinical investigators, vendors, API developers, laboratories, ingredients producers and other subcontractors

Another purpose of this partnership is also to help satisfying the growing needs of CROs and pharmaceutical companies for more GCP trained physicians-investigators and qualified clinical research coordinators, familiar in details with the ICH GCP guidelines and applicable laws and regulations. The final goal is to provide more participants in clinical trials on new drugs and devices and generate high quality results in order to contribute in increasing the role of Canada as a preferred destination for the conduct of clinical research studies.

No Comments

Sorry, the comment form is closed at this time.